Lipoatrophy with insulin analogues in type I diabetes

Babiker, Amir; Datta, Vipan
January 2011
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Jan2011, Vol. 96 Issue 1, p101
Academic Journal
Lipoatrophy is a rare complication of treatment with insulin analogues. It has been reported with insulin Lispro (Eli Lilly, Indianapolis, Indiana, USA) and insulin Glargine (Sanofi-Aventis, Paris, France). To our knowledge, this is one of the first reports of lipoatrophy with Aspart, biphasic Aspart and Detemir insulin analogues (Novo Nordisk, Bagsvaerd, Denmark). We report the cases of four children with type I diabetes who were commenced on NovoMix 30 or NovoRapid/Levemir insulin injections. They developed lipoatrophy at the injection sites after 2-3 years of treatment. In two of our patients, lipoatrophy resolved when the injection sites were changed, suggesting that local factors could be the cause of lipoatrophy. However, lipoatrophy developed at the new sites in the other two patients, requiring a change of insulin preparation. Regular examination of the injection sites facilitated early detection of lipoatrophy in our patients. Lipoatrophy completely resolved over 1-2 years in all patients with no recurrence after 3-4 years of follow-up.


Related Articles

  • The little hand is on the... Ukens, Carol // Drug Topics;7/07/2003, Vol. 147 Issue 13, p71 

    Reports on results of a study which showed that the GlucoWatch Biographer enables Type 1 diabetic children who used it to detect hypoglycemic events.

  • Insulin aspart as safe and effective as insulin lispro in children. Kalvaitis, Katie // Endocrine Today;1/10/2008, Vol. 6 Issue 1, p34 

    This article discusses research being done on the use of continuous subcutaneous insulin aspart infusion and insulin lispro in children and adolescents with type 1 diabetes. It references a study by S. A. Weinzimer et al., published in a 2007 issue of the journal "Diabetes Care." According to...

  • Type 1 diabetes:recent developments. Devendra, Devasenan; Liu, Edwin; Eisenbarth, George S. // BMJ: British Medical Journal (International Edition);3/27/2004, Vol. 328 Issue 7442, p750 

    This article presents a study on recent advances in our understanding of the epidemiology, pathogenesis, prediction, and prevention of type 1 diabetes and new treatments for the disease. Type 1 diabetes is one of the most common chronic childhood illnesses, affecting 18 to 20 per 100,000...

  • Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Weinzimer, Stuart A.; Steil, Garry M.; Swan, Karena L.; Dziura, Jim; Kurtz, Natalie; Tamborlane, William V. // Diabetes Care;May2008, Vol. 31 Issue 5, p934 

    OBJECTIVE -- The most promising β-cell replacement therapy for children with type 1 diabetes is a closed-loop artificial pancreas incorporating continuous glucose sensors and insulin pumps. The Medtronic MiniMed external physiological insulin delivery (ePID) system combines an external pump...

  • Wykorzystanie agility jako formy rekreacji w leczeniu dzieci z cukrzycÄ… typu 1 - doniesienie wstÄ™pne. Niewiadomska, Monika; Radziejewska, Marija; Horodnicka-Józwa, Anita; Petriczko, Elżbieta // Pediatric Endocrinology, Diabetes & Metabolism;2010, Vol. 16 Issue 2, p89 

    Introduction: Physical activity is a very important element in treatment of children with type 1 diabetes. However, it is difficult to find suitable exercises for the children due to their specific needs and psychophysiological condition. The aim of this study was to examine the effects of...

  • Influence of and Optimal Insulin Therapy for a Low-Glycemic Index Meal in Children With Type 1 Diabetes Receiving Intensive Insulin Therapy. Ryan, Rochelle L.; King, Bruce R.; Anderson, Donald G.; Attia, John R.; Collins, Clare E.; Smart, Carmel E. // Diabetes Care;Aug2008, Vol. 31 Issue 8, p1485 

    OBJECTIVE--The purpose of this study was to quantify the effects of glycemic index on postprandial glucose excursion (PPGE) in children with type 1 diabetes receiving multiple daily injections and to determine optimal insulin therapy for a low-glycemic index meal. RESEARCH DESIGN AND...

  • Transition from Insulin to Oral Sulfonylurea Therapy in Children with Diabetes Due to Activating Mutations in KCNJ11. Greeley, Siri Atma W.; Bordini, Brian D.; Edidin, Deborah V.; Littlejohn, Elizabeth E.; Philipson, Louis H. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA699 

    Activating mutations in KCNJ11 are a common cause of permanent neonatal diabetes mellitus (PNDM) often misdiagnosed as type 1 diabetes mellitus (T1DM). Recent reports have shown these previously insulin treated patients can be switched to oral sulfonylurea therapy. We describe here the...

  • Neonatal morbidity in infants of diabetic mothers. Gamsu, H. R. // Journal of the Royal Society of Medicine;Mar1978, Vol. 71 Issue 3, p211 

    The article presents description on the problems encountered by the King's College Hospital PLC from 1968 to 1976 on live-born infants whose diabetic mothers are treated with insulin and carbohydrate restriction during pregnancy and after delivery. These infants are found to have hyperinsulinism...

  • Repaglinide Acutely Amplifies Pulsatile Insulin Secretion by Augmentation of Burst Mass With No Effect on Burst Frequency. Juhl, Claus B.; Porksen, Niels; Hollingdal, Malene; Sturis, Jeppe; Pincus, Steven; Veldhuis, Johannes D.; Dejgaard, Anders; Schmitz, Ole // Diabetes Care;May2000, Vol. 23 Issue 5, p675 

    Focuses on a study which explored actions of repaglinide, an oral hypoglycemic agent, on the rapid pulsatile insulin release by high-frequency insulin sampling and analysis of insulin-concentration time series. Research design and methods; Results; Conclusions.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics